Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Design Therapeutics Inc shares valued at $891,600 were purchased by Logos Global Master Fund LP on Nov 18 ’25. At $7.43 per share, Logos Global Master Fund LP acquired 120,000 shares.
Also, Logos Global Master Fund LP purchased 620,000 shares, netting a total of over 4,377,200 in proceeds.
Before that, Logos Global Master Fund LP had added 415,000 shares to its account. In a trade valued at $2,851,050, the Director bought Design Therapeutics Inc shares for $6.87 each.
As published in their initiating research note from Oppenheimer on January 07, 2026, Design Therapeutics Inc [DSGN] has been an Outperform and the price target has been revised to $18. Analysts at Leerink Partners upgraded the stock from ‘”a Market perform”‘ to ‘”an Outperform”‘ outlook in a report released in early December. As of December 03, 2025, Craig Hallum has initiated its “Buy” rating for DSGN. Earlier on November 20, 2025, RBC Capital Mkts upgraded its rating. Their new recommendation was “an Outperform” for DSGN stock which previously was a “a Sector perform”.
Analyzing DSGN Stock Performance
On last trading session, Design Therapeutics Inc [NASDAQ: DSGN] rose 11.20% to $10.62. The stock’s lowest price that day was $9.535, but it reached a high of $10.7999 in the same session. During the last five days, there has been a surge of approximately 8.37%. Over the course of the year, Design Therapeutics Inc shares have jumped approximately 118.07%.
Is Design Therapeutics Inc subject to short interest?
Stocks of Design Therapeutics Inc saw a sharp rise in short interest on 2025-12-31 jumping by 0.13 million shares to 2.23 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 2.11 million shares. A jump of 5.66% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 4.45 of the overall float, the days-to-cover ratio (short ratio) jumped to 4.45.
Which companies own the most shares of Design Therapeutics Inc (DSGN)?
In terms of Design Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 15 in the next 12 months, up nearly 57.07% from the previous closing price of $9.55. Analysts anticipate Design Therapeutics Inc stock to reach 18 by 2026, with the lowest price target being 14. In spite of this, 2 analysts ranked Design Therapeutics Inc stock as Buy at the end of 2026. On May 07, 2024, Piper Sandler assigned a price target of “an Overweight” to the stock and upgraded coverage with a $12.
